Trial · NCT01729754
Outcomes33
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 33
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) | Week 12 | Analysis population includes all randomized participants who received at least 1 dose of Part 1 study treatment based on the treatment assigned. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Part 1) | Week 12 | Analysis population includes all randomized participants who received at least 1 dose of Part 1 study treatment based on the treatment assigned. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12 (Part 1) | Up to Week 12 | Analysis population includes participants who took at least one dose of Part 1 study drug based on the treatment actually received. | Percentage of participants | NUMBER |
| PRIMARY | Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 12 (Part 1) | Up to Week 12 | Analysis population includes participants who took at least one dose of Part 1 study medication based on the treatment actually received. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-75 Response at Week 28 (Part 2) | Week 28 | Analysis population includes all participants randomized to tildrakizumab or etanercept in Part 1 who received at least one dose of study medication in Part 2. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-75 Response at Week 40 (Part 3) | Week 40 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 40. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-75 Response at Week 52 (Part 3) | Week 52 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 52. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 28 (Part 2) | Week 28 | Analysis population includes participants randomized to tildrakizumab 100 mg, tildrakizumab 200 mg, or etanercept in Part 1 who received at least one dose of study medication in Part 2. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 40 (Part 3) | Week 40 | Participants who received at least one dose of study medication in Part 3 and with valid PGA value at baseline and at Week 40. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With a PGA Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 52 (Part 3) | Week 52 | Participants who received at least one dose of study medication in Part 3 and with valid PGA value at baseline and at Week 52. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-90 Response at Week 12 (Part 1) | Week 12 | Analysis population includes randomized participants who received at least one dose of study medication in study Part 1. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-90 Response at Week 28 (Part 2) | Week 28 | Analysis population includes participants randomized to tildrakizumab 100 mg, tildrakizumab 200 mg, or etanercept in Part 1 who received at least one dose of study medication in study Part 2. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-90 Response at Week 40 (Part 3) | Week 40 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 40. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-90 Response at Week 52 (Part 3) | Week 52 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 52. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-100 Response at Week 12 (Part 1) | Week 12 | Analysis population includes randomized participants who received at least one dose of study medication in study Part 1 and with valid PASI value at baseline and Week 12. | Perentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-100 Response at Week 28 (Part 2) | Week 28 | Analysis population includes participants randomized to tildrakizumab 100 mg, tildrakizumab 200 mg, or etanercept in Part 1 who received at least one dose of study medication in study Part 2. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-100 Response at Week 40 (Part 3) | Week 40 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 40. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Achieving a PASI-100 Response at Week 52 (Part 3) | Week 52 | Participants who received at least one dose of study medication in Part 3 and with valid PASI value at baseline and at Week 52. | Percentage of participants | NUMBER |
| SECONDARY | Baseline Dermatology Life Quality Index (DLQI) | Baseline | Analysis population includes randomized participants who received at least one dose of study medication with baseline and post-baseline DLQI values in Part 1. | Score on a scale | MEAN |
| SECONDARY | Change From Baseline in the DLQI at Week 12 (Part 1) | Baseline and Week 12 | Analysis population includes randomized participants who received at least one dose of study medication with baseline or post-baseline DLQI values in Part 1. | Score on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01729754/outcomes